Previous 10 | Next 10 |
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, toda...
2023-11-09 21:56:04 ET Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Conference Call November 09, 2023, 04:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Commercial Officer Lisa Walters-Hoffert - CFO Confer...
2023-11-09 08:16:03 ET More on Dare Bioscience Dare Bioscience Q3 2023 Earnings Preview Daré Bioscience's stock rises ~15% on $1.8M milestone from Organon for Xaciato Seeking Alpha’s Quant Rating on Dare Bioscience Historical earnings data for Dar...
Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™ : receipt of $1.8 million triggered by achievement of first commercial milestone under license agreement with Organon Ovaprene® : commencement of pivotal...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Dare Bioscience Inc. (DARE) is expected to report $-0.1 for Q3 2023
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s President and CEO, Sabrina Martucci Johnson, and Medical Advisor Andrew T. Goldstein, MD, will partic...
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 9, 2023, to review its financial results ...
Additional Analyses of Phase 2b Data Conducted in Population of Study Participants with Female Sexual Interest/Arousal Disorder (FSIAD), With Primary Complaint of Arousal Dysfunction Achieved Statistical Significance and Clinically Meaningful Improvement in Phase 2b Co-Primary Endpo...
2023-10-16 10:59:42 ET More on Dare Bioscience Seeking Alpha’s Quant Rating on Dare Bioscience Dare Bioscience to sell 10M shares at $0.70 in registered direct offering Historical earnings data for Dare Bioscience For further details see: Daré...
News, Short Squeeze, Breakout and More Instantly...
2024-07-01 09:02:05 ET Dare Bioscience Inc (DARE) announced stock split at a ratio of 1-for-12 on 2024-07-01 ... Full story available on KlickAnalytics.com
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split...
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies fo...